Loading provider…
Loading provider…
Hematology & Oncology Physician in Richmond, VA
NPI: 1205887270Primary Practice Location
MEDICAL COLLEGE OF VIRGINIA HOSPITALS
1213 E Clay St, Richmond, VA
Primary Employer
MCV Associated Physicians
vcuhealth.org
HQ Phone
Get MD Bruce's Phone Numberphone_androidMobile
Get MD Bruce's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardVA State Medical License
FL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 95 | 127 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 77 | 129 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 34 | 34 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 24 | 76 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
Authors: Yoshihiro Komatsu, Astha Bhatt, Usha Malhotra, Toshitaka Hoppo
Journal: Ann Surg
New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.
Authors: Victor Yazbeck, Patrick Willard, Ariel Sindel
Journal: Expert Opin Pharmacother
Publication Date: 2024-08-21
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Laboratory Biomarker Analysis, DRUG: Cyclophosphamide, DRUG: Paclitaxel, DRUG: Doxorubicin Hydrochloride